Cargando…

Combination of denosumab and biologic DMARDs in inflammatory muscle-skeletal diseases and connective tissue diseases

Mostrar otras versiones (1)

OBJECTIVE: Osteoporosis (OP) can complicate the course of rheumatic musculoskeletal diseases (RMDs) and connective tissue diseases (CTDs). Denosumab, a monoclonal antibody against RANK-L, showed beneficial effect in rheumatoid arthritis in inhibiting radiographic progression and erosive burden. We t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bruni, Cosimo, Cigolini, Cosimo, Tesei, Giulia, Cometi, Laura, Bartoli, Francesca, Fiori, Ginevra, Nacci, Francesca, Bellando-Randone, Silvia, Guiducci, Serena, Matucci-Cerinic, Marco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medical Research and Education Association 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10176238/ https://www.ncbi.nlm.nih.gov/pubmed/34059186 http://dx.doi.org/10.5152/eurjrheum.2020.21162

Ejemplares similares

Combination of denosumab and biologic DMARDs in inflammatory muscle-skeletal diseases and connective tissue diseases
por: Bruni, Cosimo, et al.
Publicado: (2022)

Effect of Dysmetabolisms and Comorbidities on the Efficacy and Safety of Biological Therapy in Chronic Inflammatory Joint Diseases
por: Cometi, Laura, et al.
Publicado: (2020)

Baricitinib in the treatment of rheumatoid arthritis: clinical and ultrasound evaluation of a real-life single-centre experience
por: Tesei, Giulia, et al.
Publicado: (2021)

The positive side of the coin: Sars-Cov-2 pandemic has taught us how much Telemedicine is useful as standard of care procedure in real life
por: El Aoufy, Khadija, et al.
Publicado: (2021)

Risk of Malignancy and Biologic Therapy in Rheumatic Inflammatory Diseases: A Single-center Experience
por: Cometi, Laura, et al.
Publicado: (2020)

The systemic sclerosis patient in the COVID-19 era: the challenging crossroad between immunosuppression, differential diagnosis and long-term psychological distress
por: Orlandi, Martina, et al.
Publicado: (2020)

Switching from originator adalimumab to biosimilar SB5 in a rheumatology cohort: persistence on treatment, predictors of drug interruption and safety analysis
por: Bruni, Cosimo, et al.
Publicado: (2021)

The switch from etanercept originator to SB4: data from a real-life experience on tolerability and persistence on treatment in joint inflammatory diseases
por: Bruni, Cosimo, et al.
Publicado: (2020)

The Role of Bronchoalveolar Lavage in Systemic Sclerosis Interstitial Lung Disease: A Systematic Literature Review
por: Orlandi, Martina, et al.
Publicado: (2022)

The “myth” of loss of angiogenesis in systemic sclerosis: a pivotal early pathogenetic process or just a late unavoidable event?
por: Matucci-Cerinic, Marco, et al.
Publicado: (2017)

Systemic Sclerosis Sera Impair Angiogenic Performance of Dermal Microvascular Endothelial Cells: Therapeutic Implications of Cyclophosphamide
por: Borghini, Annalisa, et al.
Publicado: (2015)

Vascular Leaking, a Pivotal and Early Pathogenetic Event in Systemic Sclerosis: Should the Door Be Closed?
por: Bruni, Cosimo, et al.
Publicado: (2018)

Plexin-D1/Semaphorin 3E pathway may contribute to dysregulation of vascular tone control and defective angiogenesis in systemic sclerosis
por: Mazzotta, Celestina, et al.
Publicado: (2015)

Lung Ultrasound B-Lines in the Evaluation of the Extent of Interstitial Lung Disease in Systemic Sclerosis
por: Bruni, Cosimo, et al.
Publicado: (2022)

Interstitial lung disease in systemic sclerosis: where do we stand?
por: Cappelli, Susanna, et al.
Publicado: (2015)

Oral Lactobacillus Species in Systemic Sclerosis
por: Melchiorre, Daniela, et al.
Publicado: (2021)

Proangiogenic effects of soluble α-Klotho on systemic sclerosis dermal microvascular endothelial cells
por: Mazzotta, Celestina, et al.
Publicado: (2017)

Pleuroparenchymal fibroelastosis in patients affected by systemic sclerosis: What should the rheumatologist do?
por: Bargagli, Elena, et al.
Publicado: (2019)

The Use and Utility of Machine Learning in Achieving Precision Medicine in Systemic Sclerosis: A Narrative Review
por: Bonomi, Francesco, et al.
Publicado: (2022)

Potential Role of JAK Inhibitors in the Treatment of Systemic Sclerosis-Associated Interstitial Lung Disease: A Narrative Review from Pathogenesis to Real-Life Data
por: Fiorentini, Elisa, et al.
Publicado: (2022)

The Yin-Yang Pharmacomicrobiomics on Treatment Response in Inflammatory Arthritides: A Narrative Review
por: Peretti, Silvia, et al.
Publicado: (2022)

Menstruation-Related Disorders—Dysmenorrhea and Heavy Bleeding—as Significant Epiphenomena in Women With Rheumatic Diseases
por: Orlandi, Martina, et al.
Publicado: (2022)

The Emerging Challenge of Pain in Systemic Sclerosis: Similarity to the Pain Experience Reported by Sjőgren’s Syndrome Patients
por: De Luca, Rossella, et al.
Publicado: (2021)

Systemic Sclerosis Association with Malignancy
por: Lepri, Gemma, et al.
Publicado: (2022)

Exploring the Oral Microbiome in Rheumatic Diseases, State of Art and Future Prospective in Personalized Medicine with an AI Approach
por: Bellando-Randone, Silvia, et al.
Publicado: (2021)

Systemic Sclerosis Patients Experiencing Mindfulness-Based Stress Reduction Program: The Beneficial Effect on Their Psychological Status and Quality of Life
por: El Aoufy, Khadija, et al.
Publicado: (2023)

Angiogenic T cell expansion correlates with severity of peripheral vascular damage in systemic sclerosis
por: Manetti, Mirko, et al.
Publicado: (2017)

Systemic Sclerosis Serum Significantly Impairs the Multi-Step Lymphangiogenic Process: In Vitro Evidence
por: Manetti, Mirko, et al.
Publicado: (2019)

Computed Tomography Predictors of Mortality or Disease Progression in Systemic Sclerosis–Interstitial Lung Disease: A Systematic Review
por: Landini, Nicholas, et al.
Publicado: (2022)

Decreased expression of the endothelial cell-derived factor EGFL7 in systemic sclerosis: potential contribution to impaired angiogenesis and vasculogenesis
por: Manetti, Mirko, et al.
Publicado: (2013)

The Role of Endogenous Eicosapentaenoic Acid and Docosahexaenoic Acid-Derived Resolvins in Systemic Sclerosis
por: Avanoǧlu Güler, Aslıhan, et al.
Publicado: (2020)

Open questions on the management of targeted therapies for the treatment of systemic sclerosis-interstitial lung disease: results of a EUSTAR survey based on a systemic literature review
por: Campochiaro, Corrado, et al.
Publicado: (2022)

Lymphatic Endothelial-to-Myofibroblast Transition: A Potential New Mechanism Underlying Skin Fibrosis in Systemic Sclerosis
por: Rosa, Irene, et al.
Publicado: (2023)

Safety and efficacy of biological therapy with TNF-inhibitors and non TNF-inhibitors in a cohort of young adults affected by juvenile idiopathic arthritis (JIA): data from a single centre experience
por: Lorenzo, Ceri, et al.
Publicado: (2011)

Cardiac magnetic resonance predicts ventricular arrhythmias in scleroderma: the Scleroderma Arrhythmia Clinical Utility Study (SAnCtUS)
por: Mavrogeni, Sophie, et al.
Publicado: (2020)

COVID-19 and systemic sclerosis: Rising to the challenge of a pandemic
por: Denton, Christopher P, et al.
Publicado: (2020)

Risk of infection in postmenopausal women with rheumatoid arthritis and osteoporosis taking denosumab and bDMARDS
por: Mirzaei, Alireza, et al.
Publicado: (2021)

Interleukin-1 and Systemic Sclerosis: Getting to the Heart of Cardiac Involvement
por: De Luca, Giacomo, et al.
Publicado: (2021)

The crowded crossroad to angiogenesis in systemic sclerosis: where is the key to the problem?
por: Manetti, Mirko, et al.
Publicado: (2016)

Systemic sclerosis sera affect fibrillin-1 deposition by dermal blood microvascular endothelial cells: therapeutic implications of cyclophosphamide
por: Villano, Marilisa, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_4tu8lbdjq1pn7jvvrj8nvc8vo6